share_log

Piper Sandler Maintains Overweight on Kymera Therapeutics, Raises Price Target to $56

Moomoo 24/7 ·  Feb 27 10:27

Piper Sandler analyst Edward Tenthoff maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $39 to $56.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment